First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort.

Clin Med Insights Oncol · 2026 · PMC12936372 · PMID 41769085

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

These differences did not reach statistical significance ( P > 0.05).

also in 111,027 other papers

showed a trendno p-value reported

9 Furthermore, both median PFS and OS in our study showed a trend toward longer survival than those observed in a phase II study by Ozaka et al, 10 which evaluated the efficacy mFOLFIRINOX in 69 chemotherapy-naïve Japanese patients (5.5 (95% CI, 4.1-6.7) and 11.2 (95% CI, 9.0-not reached) months, respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.